[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359074-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359074-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-nhej-activates-sting-signaling-through-myc-degradation-to-boost-antitumor-immunity-in-sclc","Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC","","Small-cell lung cancer (SCLC) shows a high mutation burden yet limited immunotherapy responses, creating an unmet clinical need. Across 24 tumor types and more than 179,000 real-world patient tumors, the NHEJ DNA repair regulator PRKDC (DNAPKcs) is highest in SCLC, and high PRKDC predicts poor immunotherapy response. DNAPKcs depletion activates the cGAS/STING pathway via cytoplasmic double-stranded DNA accumulation, promotes immunogenicity, and increases sensitivity to immunotherapy models. Mechanistically, DNAPKcs depletion triggers proteasomal MYC degradation through the GSK3β pathway.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-nhej-activates-sting-signaling-through-myc-degradation-to-boost-antitumor-immunity-in-sclc/359074/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-nhej-activates-sting-signaling-through-myc-degradation-to-boost-antitumor-immunity-in-sclc/359074.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is immunotherapy response in SCLC considered limited?","Question",{"text":63,"@type":64},"SCLC is highly aggressive and often exhibits an immunosuppressed tumor microenvironment, resulting in relatively low infiltrating T-cells and reduced antigen presentation. Consequently, only a small fraction of patients achieve deep, durable responses to immune checkpoint blockade.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the role of PRKDC (DNAPKcs) in SCLC immunotherapy response?",{"text":68,"@type":64},"Across many tumor types, PRKDC (DNAPKcs) expression is highest in SCLC. High PRKDC expression predicts poor immunotherapy response, and reducing DNAPKcs enhances immunotherapy sensitivity.",{"name":70,"@type":61,"acceptedAnswer":71},"How does DNAPKcs depletion enhance antitumor immunity?",{"text":72,"@type":64},"DNAPKcs depletion activates the cGAS/STING pathway through cytoplasmic accumulation of double-stranded DNA, increasing immunogenicity. It also induces proteasomal degradation of MYC via the GSK3β pathway, supporting a mechanism for improved antitumor immune responses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359074,1790189363,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Article [https://doi.org/10.1038/s41467-026-69262-x](https://doi.org/10.1038/s41467-026-69262-x)  \nTargeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC  \nReceived: 27 November 2024  \n\n| Accepted: 28 January 2026 |\n| --- |\n| |\n| Check for updates |\n\nSubhamoy Chakraborty1, Andrew Elliott 2, Utsav Sen3, Charles Coleman4,5, Vrinda Jethalia4,5, Kedwin Ventura3, Chih-Wei Fan4,5, Ramja Sritharan3, Avisek Banerjee3, Yazhini Mahendravarman3, Ari Vanderwalde 2,  \nBalazs Halmos 6, Elisa de Stanchina7, Hirokazu Taniguchi8,9,  \nDeniz Demircioglu 3,4,5, Dan Hasson3,4,5 & Triparna Sen 1   \nSmall-cell lung cancer (SCLC) is the most lethal type of lung cancer. Paradoxically, this tumor displays a high mutation burden; however, a modest response to immunotherapy. Improving Immunotherapy response in SCLC patients remains an unmet need. Here, we report that across 24 tumor types, including over 179,000 real-world patient tumors, SCLC has the highest expression of nonhomologous end joining (NHEJ) DNA repair regulator PRKDC (DNAPKcs). High PRKDC expression predicts poor response to immunotherapy in SCLC. DNAPKcs depletion causes activation ofcGAS/STING pathway due to cytoplasmic accumulation of double-stranded DNA, inducing immunogenicity and enhancing sensitivity of SCLC models to immunotherapy. Analyses in SCLC cell lines and mouse models shows that depletion of DNAPKcs leads to proteasomal degradation of MYC via GSK3β pathway. We show that DNAPKcs upregulation contributes to immunotherapy resistance and DNAPKcs inhibition represents a promising therapeutic strategy to induce antitumor immunity and potentiate immunotherapy efﬁcacy in immunologically suppressed SCLC.  \nSmall cell lung cancers (SCLCs) are highly aggressive neuroendocrine cancers that account for 15% of all lung cancer cases, with a median overall survival of only 9–11 months1,2. SCLC accounts for 30,000 new cases diagnosed annually in the United States and has an overall 5-year survival rate of about 7%3. While treatment options have recently broadened, however, overall outcomes only modestly improved, indicating a pressing need for novel therapies. The recent addition of surface-targeted drugs shows promise but is also accompanied by severe toxicities4. Efforts to expand the therapeutic arsenal toward  \nSCLC have focused on immune checkpoint blockade (ICB) using agents targeting programmed cell death protein 1 (PD-1) and its ligand (programmed death ligand 1 [PD-L1]). One particularly understudied but common feature of SCLC is an immunosuppressed phenotype characterized by relatively low levels of inﬁltrating T-cells, suppression of class I major histocompatibility complex (MHC-I), or reduced antigen presentation5. Consistent with a compromised tumor microenvironment immune milieu, only a few patients with SCLC have a deep and durable response to ICB. The approved ﬁrst-line treatment of  \n1Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA. 2Department of Clinical and Translational Research, Caris Life Sciences Inc., Tempe, Arizona, USA. 3Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 4Tisch Cancer Institute, Mount Sinai, New York, NY, USA. 5Tisch Cancer Institute Bioinformatics for Next Generation Sequencing (BiNGS) core, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 6Monteﬁore Medical Center, Albert Einstein College of Medicine, New York, NY, USA. 7Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan. 9Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. e-mail: [triparna.sen@osumc.edu](triparna.sen@osumc.edu)  \nplatinum doublet and PD-L1 blockade leads to a modest increase in overall survival by approximately 2 months2,6–8. The mechanisms pre","cbCaidRmZQSllJPT","https://ap.wps.com/l/cbCaidRmZQSllJPT","pdf",3763812,23,"English","# Background and clinical need\n## Immunotherapy limitations in SCLC\n# Key findings and evidence\n## PRKDC (DNAPKcs) expression across tumor types\n## cGAS/STING activation after DNAPKcs depletion\n# Mechanistic pathway\n## GSK3β-mediated MYC proteasomal degradation","[{\"question\":\"Why is immunotherapy response in SCLC considered limited?\",\"answer\":\"SCLC is highly aggressive and often exhibits an immunosuppressed tumor microenvironment, resulting in relatively low infiltrating T-cells and reduced antigen presentation. Consequently, only a small fraction of patients achieve deep, durable responses to immune checkpoint blockade.\"},{\"question\":\"What is the role of PRKDC (DNAPKcs) in SCLC immunotherapy response?\",\"answer\":\"Across many tumor types, PRKDC (DNAPKcs) expression is highest in SCLC. High PRKDC expression predicts poor immunotherapy response, and reducing DNAPKcs enhances immunotherapy sensitivity.\"},{\"question\":\"How does DNAPKcs depletion enhance antitumor immunity?\",\"answer\":\"DNAPKcs depletion activates the cGAS/STING pathway through cytoplasmic accumulation of double-stranded DNA, increasing immunogenicity. It also induces proteasomal degradation of MYC via the GSK3β pathway, supporting a mechanism for improved antitumor immune responses.\"}]","Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC | PDF",1790136040,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65180bc1cbf8191c7d576241a153fd16.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2a594bbb091ef75f0cdf5f91c378df6.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ba4fc1898df2fd23b8c8b9b2e64ecbe.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/663ac74d21666fece9c4e959cd41fe35.webp",980,1301]